Best endocrinologists: TOP 148 doctors

Dr. Ajith Kumar is an Endocrinologist with 18 years of experience as a Consultant. He began his career as an Endocrinology Senior Resident at PGIMER, Chandigarh. After obtaining a DM in Endocrinology, he completed 15 years of clinical practice. He served as an Assistant Professor in the Department of Endocrinology at medical colleges associated with NTR University of Health Sciences for two years. Andhra Pradesh, India. He has served as a Consultant Endocrinologist for three years in multiple multispecialty hospitals in Kerala, India. He has been practicing as an Endocrinologist in Dubai for the past nine years.

Expertise

Type 2 Diabetes, Type 1 Diabetes, And Diabetes in Pregnancy (GDM)

Thyroid Function Abnormalities

Thyroid Nodules, Thyroid Cancer Management, and Follow-Up

Pituitary Gland Disorders, Including Tumors

Hormone Induced Hypertension

Adrenal Gland Disorders

Growth Disorders

Disorders of Puberty

PCOS and other Ovarian Disorders

Testicular Disorders

Obesity

Hyperlipidemia, Hyperuricemia, and Other Metabolic Conditions

Osteoporosis, Vitamin D Deficiency, and Other Metabolic Bone Disorders Including Parathyroid Abnormalities

Membership

American Association of Clinical Endocrinology (AACE)

The Endocrine Society

Endocrine Society of India and Indian Thyroid Society

Indian Association of Physicians

Biography

Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:

• Oncology care and treatment for chemotherapy, hormonal therapy, immune therapy, and target therapy
• Breast cancer
• Solid tumor diagnosis
• Digestive cancer
• Gynecological cancer
• Lung cancer
• Genitourinary cancer
• Sarcoma

Awards & Achievements

• Award from Himaya Foundations and University of Sharjah

Research & Publications

• Clinicopathological Features of Gastric Cancer in a Cohort of Gulf Council Countries' Patients: A Cross-Sectional Study of 96 Cases. Journal of Oncology Research Reviews & Reports Volume 2(2): 1-3.
• The Burden of Gynecologic Cancers in the UAE. Journal of Oncology Research Reviews & Reports Volume 2(4): 1-6.
• The Emirates Oncology Task Force Clinical Practice Guideline on Screening for SARS-CoV-2 in Asymptomatic Adult Cancer Patients Before Anti-Cancer Therapy. Journal of Oncology Research Reviews & Reports Volume 2(4): 1-6.
• The State of Cancer Care in the United Arab Emirates in 2020: Challenges and Recommendations, A report by the United Arab Emirates Oncology Task Force. Humaid Al-Shamsi, Humaa Darr, Ibrahim Abu-Gheida , Jawaher Ansari, Martine, Mehdi Afrit, Mohamad H Masri, Mohamed Abuhaleeqa. Gulf J Oncology 2020 Jan;1(32):71-87.
• Primary Bone Lymphoma: Tunisian Multicentric Retrospective Study About 32 Cases. Ben Ayed C, Laabidi S, Said N, Afrit M, Ben Ahmed S, Boussen H. Tunis Med. 2018 May;96(5):269-272.
• First Site of Recurrence After Breast Cancer Adjuvant Treatment in the Era of Multimodality Therapy: Which Imaging for Which Patient During Follow-up? Nesrine M, Mehdi B, Houda EB, Soumaya L, Mehdi A, Bechir Z, Hamouda B. Breast Dis. 2017 Nov 21

• Specializes in treating diabetes, thyroid disorders, and hormonal imbalances.
• International practice includes guidance for patients seeking treatments abroad.
• Offers remote consultations for global patients with endocrine disorders.

Prof. Andrea Lania has graduated at the Università degli Studi of Milan and is specialized in endocrinology. He is the Unit Director of Endocrinology and Diabetology in Humanitas Research Hospital and his specialization is pituitary diseases, pituitary adenomas, thyroid cancer, pancreatic neuroendocrine tumors, poorly differentiated neuroendocrine carcinomas.

Medical areas of interest:
Pituitary tumors, hypopituitarism, acromegaly, Cushing’s disease and syndrome, neuroendocrine tumors, thyroid and thyroid diseases, adrenal and adrenal diseases, hypogonadism.

Research areas of interest:
Study of the pathogenetic mechanisms of pituitary and neuroendocrine tumors, of the molecular mechanisms responsible for the different response of pituitary and neuroendocrine tumors to medical therapy.

Prof. Lania published 198 peer-reviewed papers (Google Scholar H-Index 47; Scopus H-Index 38, cit tot 4604)

Prof. Lania has a long standing expertise in the field of intra-cellular signaling in endocrine tumors. In particular, in the past ten years, he contributed to analyze the role of PKA regulatory subunits in the pathogenesis and control of cell proliferation of endocrine tumors. Moreover, he contributed to define the role of SSTR5 domains involved in the intracellular trafficking of this receptor in human pituitary cells and to analyze the impact of DR2R and SSTR2&5 polymorphic variants on both the clinical outcome and response to medical treatment in patients with pituitary tumors.

Recently, he contributed to identify the role of cytoskeleton protein FLNA in mediating both intracellular signaling and membrane targeting of somatostatin type 2 receptor and D2R in pituitary and pancreatic neuroendocrine tumors. Finally, he contributed to explore the intracellular mechanisms possibly involved in mediating the interplay between drugs commonly used in the treatment of neuroendocrine tumors.

Previous experience:
2005-2008 Fondazione Ospedale Maggiore Policlinico IRCCS, Milan, Italy
Director of Endocrinologic Day Hospital and surgery on pituitary disorders. 

Publications: https://www.ncbi.nlm.nih.gov/pubmed?term=lania%20A